secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001737287-25-000035
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q4 net loss $59.9M; cash $373.1M; pipeline milestones 2025-2027
--------------------------------------------------------------------------------

- Q4 net loss $59.9M ($0.28/share); FY net loss $257.6M ($1.32/share); R&D expense $45M Q4.
- Cash & investments $373.1M; cash runway into 2H 2026; 2025 guidance: ~$170M cash burn.
- ALPHA3 pivotal trial for cema-cel in 1L LBCL: 40 sites activated; futility analysis mid-2025; primary EFS data YE2026.
- ALLO-329 autoimmune: IND cleared; RESOLUTION basket trial start mid-2025; proof-of-concept data YE2025.
- ALLO-316 RCC: Phase 1b expansion fully enrolled; data mid-2025; RMAT designation received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728725000035/0001737287-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728725000035/allo-20250313.htm
  HTML page:      https://secwatch.observer/filing/0001737287-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer